GID BIO BLOG
Read Updates from GID BIO.
GID BIO, a cellular therapy company, moves a step closer to potentially helping relieve the $200 billion osteoarthritis burden on the U.S. healthcare system
AMA grants two Category III CPT® codes, paving the way for reimbursement strategies GID BIO’s unique autologous cellular implant derived from adipose tissue is produced with its SVF-2 device and is injected into the knee intended to treat pain and function associated with osteoarthritis (OA). This procedure warrants two new
GID BIO complete pivotal Phase IIb clinical trial
GID BIO completed a pivotal Phase IIb clinical trial with an FDA-compliant study design using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results… Read more via ORTHOWORLD: https://www.orthoworld.com/index.php/publications/orthoflash/gid-bio-completes-trial-of-stromal-cells-to-treat-knee-oa
Interventional Orthopedics and cell-based therapy
Companies and clinics tout the promise of cellular therapy (usually as a “stem cell therapy”) backed by little more than anecdotal evidence and the hypothetical possibility of efficacy. When we launched GID BIO, we committed to ensuring that every device and procedure that bears our name is backed by sound
Interventional Orthopedics and cell-based therapy
Companies and clinics tout the promise of cellular therapy (usually as a “stem cell therapy”) backed by little more than anecdotal evidence and the hypothetical possibility of efficacy. When we launched GID BIO, we committed to ensuring that every device and procedure that bears our name is backed by sound